

**PDUFA V The Program Internal Late Cycle Meeting**  
**STN 125566/0**  
**Factor VIII (Recombinant), PEGylated**  
**Baxter Healthcare Corporation**

**July 7, 2015, 1 to 2 p.m.**  
**White Oak Building 71, Room 1208/1210**

**Internal Late Cycle Meeting Agenda:**

1. Review Team Introductions

Chair Person: Dr. Ze Peng  
Clinical Reviewer: Dr. Stephanie Omokaro  
CMC Product Reviewer: Dr. Alexey Khrenov  
Clinical Pharmacology: Dr. Carl-Michael Staschen  
Toxicology Reviewer: Dr. La’Nissa Brown  
DMPQ Reviewer: CMDR Jeremy Wally  
DMPQ Reviewer: Anthony Lorenzo  
OCBQ/DCM APLB Reviewer: Dr. Loan Nguyen  
OCBQ/DBSQC Representative: Karen Campbell  
OCBQ/BIMO Reviewer: Dennis Cato  
OCBQ/DBSQC Reviewer: Dr. Lokesh Bhattacharyya  
OCBQ/DBSQC Reviewer: Dr. Hyesuk Kong  
Regulatory Project Manager: Yu Do  
Regulatory Project Manager: Edward Thompson

Non-Review Team members

OBRR Director: Dr. Jay Epstein  
OBRR Deputy Director: Dr. Ginette Michaud  
OBRR Associate Director: Dr. Mark J. Weinstein  
OBRR/DHCR Division Director: Dr. Paul Mintz  
OBRR/DHCR Deputy Division Director: Dr. Howard Chazin  
OBRR/DHRR Deputy Division Director: Dr. Mahmood Farshid  
OCBQ/DMPQ Division Director: Dr. John Eltermann  
OBRR/DHRR, Laboratory of Hemostasis Acting Chief: Dr. Timothy Lee  
OBRR/DHCR, Clinical Review Branch Acting Chief: Dr. Bindu George  
OCBQ/DMPQ, Review Branch II Chief: Marion Michaelis

OBRR/DHCR, Acting Lead Medical Officer: Dr. L. Ross Pierce

OBE/DB, Therapeutics Evaluation Branch Chief: Dr. Boguang Zhen

OBE/DB, Acting Lead Mathematical Statistician: Dr. Renee Rees

OBE/DE, Analytic Epidemiology Branch Chief: Dr. Wei Hua

2. Introduction of application:

Summary Description of Product: Factor VIII (Recombinant), PEGylated Lyophilized Powder for Solution for Intravenous Injection used to treat adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency) for:

- 1) On-demand Treatment and Control of bleeding episodes
- 2) Routine prophylaxis to reduce the frequency of bleeding episodes

Ground Rules: The discussion with the applicant will not provide information of the final decision on the action due date. If the applicant requests the status for the action due we must imply the “review is on-going and issues may be added, expanded upon, or modified as we continue to review this application.”

Objective of the Meeting: This meeting with the applicant is to fulfill the transparency of the review. We can provide clarity for the applicant and discuss issues that may have an effect on the outcome of the action due date.

3. Substantive review issues/major deficiencies raised during review:

- a. CMC – Dr. Peng and Dr. Khrenov: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- b. Pharm Tox – Dr. Brown: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- c. Clin Pharm – Dr. Staschen: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- d. Clinical – Dr. Omokaro: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- e. Epidemiology – Dr. Baumblatt: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- f. Stats – Dr. Rees and Dr. Zhen: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- g. Labeling – Dr. Loan Nguyen: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- h. Facility/CMC: CMDR Wally: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.

- i. Lot Protocol and Testing: Ms. Campbell, Dr. Kong, and Dr. Bhattacharyya: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.
- j. BIMO Clinical Site Reviewer: Mr. Cato: No Substantive Issues to present to the applicant at the scheduled late-cycle meeting.

4. Review of upcoming timeline/deadlines:

Late Cycle Meeting due to applicant:	24-Jul-15	
External Telecon Late Cycle Meeting	6-Aug-15	
Inform OCOD (RPM)	31-Aug-15	
SSE/SBRA and Draft PI to Division Management (Chair)		17-Sep-15
Draft Approval Letter (RPM)	17-Sep-15	
Draft PI and Information Request to Jennifer (Chair)		17-Sep-15
SSE/SBRA+ PI + Approval Letter to OBRR Management		1-Oct-15
Comments from OBRR Management	5-Oct-15	
Press Release/Information Sheet	N/A	
Meeting with OBRR Management	5-Oct-15	
Send complete package to RPM (Chair)	16-Oct-15	
Send Final PI to sponsor (RPM)	21-Oct-15	
Route relevant documents to OBE, OCBQ, and/or ADRM (RPM)		21-Oct-15
Review Completed -- T-x Date	11-Nov-15	
Finalize package (RPM)	27-Oct-15	
Inform Jennifer - ADD (RPM)	23-Oct-15	
Route for signatures (RPM)	29-Oct-15	
OBRR Mgt Signature	2-Nov-15	
Target ADD	5-Nov-15	

5. Assess status of the review including plans for completing outstanding discipline reviews and any remaining outstanding issues.

The outstanding issues remaining for the review of this application are post marketing commitments and requirements, and revision of the product labeling including package insert assertions.

6. Reach agreement on meeting materials.

The meeting package will be prepared by the RPMs and routed to the meeting participants for review and revisions. There are no substantive issues to present to the applicant at this time in the review.

7. Come to agreement on the issues to be included on the agenda for the late-cycle meeting with the applicant. The timeframes for each agenda item should also be agreed upon.

Issue the late cycle meeting package to the applicant with no substantive issues to present at this forum.

End

History

Drafted	Edward Thompson
Revised	Ze Peng & Mark Weinstein/ September 2, 2015
Revised	Sonday L. Kelly/ July 22, 2015
Revised	Stephanie Omokaro/ September 1, 2015